BR0309397A - Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia - Google Patents

Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia

Info

Publication number
BR0309397A
BR0309397A BR0309397-2A BR0309397A BR0309397A BR 0309397 A BR0309397 A BR 0309397A BR 0309397 A BR0309397 A BR 0309397A BR 0309397 A BR0309397 A BR 0309397A
Authority
BR
Brazil
Prior art keywords
group
denotes
formula
hydrogen atom
therapy
Prior art date
Application number
BR0309397-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Gihad Dargazanli
Genevi Ve Estenne-Bouhtou
Pascale Magat
Benoit Marabout
Florence Medaisko
Pierre Roger
Mireille Sevrin
Corinne Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BR0309397A publication Critical patent/BR0309397A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0309397-2A 2002-04-19 2003-04-17 Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia BR0309397A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204916A FR2838739B1 (fr) 2002-04-19 2002-04-19 Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
PCT/FR2003/001232 WO2003089411A1 (fr) 2002-04-19 2003-04-17 Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BR0309397A true BR0309397A (pt) 2005-03-01

Family

ID=28686193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309397-2A BR0309397A (pt) 2002-04-19 2003-04-17 Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia

Country Status (35)

Country Link
US (2) US7326722B2 (enExample)
EP (1) EP1499589B1 (enExample)
JP (1) JP4597532B2 (enExample)
KR (2) KR20040103973A (enExample)
CN (1) CN100482646C (enExample)
AR (1) AR039413A1 (enExample)
AT (1) ATE361279T1 (enExample)
AU (1) AU2003262420B2 (enExample)
BR (1) BR0309397A (enExample)
CA (1) CA2481461C (enExample)
CO (1) CO5631432A2 (enExample)
CY (1) CY1108025T1 (enExample)
DE (1) DE60313602T2 (enExample)
DK (1) DK1499589T3 (enExample)
EA (1) EA007225B1 (enExample)
EC (1) ECSP045369A (enExample)
ES (1) ES2286444T3 (enExample)
FR (1) FR2838739B1 (enExample)
HR (1) HRP20040977B1 (enExample)
IL (2) IL164400A0 (enExample)
IS (1) IS2540B (enExample)
MA (1) MA27192A1 (enExample)
ME (1) MEP25608A (enExample)
MX (1) MXPA04010326A (enExample)
NO (1) NO329065B1 (enExample)
NZ (1) NZ536015A (enExample)
PL (1) PL373195A1 (enExample)
PT (1) PT1499589E (enExample)
RS (1) RS51888B (enExample)
SI (1) SI1499589T1 (enExample)
TN (1) TNSN04208A1 (enExample)
TW (1) TWI306402B (enExample)
UA (1) UA78025C2 (enExample)
WO (1) WO2003089411A1 (enExample)
ZA (1) ZA200408154B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2005044810A1 (en) * 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
CA2609972C (en) 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
MX2007012463A (es) * 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
JP2009179562A (ja) * 2006-08-11 2009-08-13 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
FR3045044B1 (fr) * 2015-12-11 2019-04-19 Liphatech Composition et appat rodonticide comprenant du flocoumafene, procede de lutte contre des rongeurs cibles nuisibles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5524569A (en) * 1995-03-20 1996-06-11 Rich; William A. Anchor cover
KR20010032967A (ko) * 1998-03-06 2001-04-25 디르크 반테 글리신 수송 저해제
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors

Also Published As

Publication number Publication date
RS51888B (sr) 2012-02-29
IS2540B (is) 2009-09-15
EP1499589A1 (fr) 2005-01-26
IL164400A (en) 2010-11-30
PT1499589E (pt) 2007-08-10
FR2838739B1 (fr) 2004-05-28
IS7479A (is) 2004-09-30
KR101019313B1 (ko) 2011-03-07
MA27192A1 (fr) 2005-01-03
CN1662497A (zh) 2005-08-31
KR20080075236A (ko) 2008-08-14
TNSN04208A1 (fr) 2007-03-12
WO2003089411A1 (fr) 2003-10-30
SI1499589T1 (sl) 2007-10-31
CN100482646C (zh) 2009-04-29
DE60313602D1 (de) 2007-06-14
TWI306402B (en) 2009-02-21
JP4597532B2 (ja) 2010-12-15
NO20044388L (no) 2005-01-19
DK1499589T3 (da) 2007-09-10
CO5631432A2 (es) 2006-04-28
US20070197601A1 (en) 2007-08-23
US7326722B2 (en) 2008-02-05
PL373195A1 (en) 2005-08-22
EA007225B1 (ru) 2006-08-25
EP1499589B1 (fr) 2007-05-02
NZ536015A (en) 2006-11-30
ES2286444T3 (es) 2007-12-01
AU2003262420A1 (en) 2003-11-03
ZA200408154B (en) 2005-10-10
EA200401172A1 (ru) 2005-04-28
TW200306830A (en) 2003-12-01
ATE361279T1 (de) 2007-05-15
ECSP045369A (es) 2005-03-10
AR039413A1 (es) 2005-02-16
AU2003262420B2 (en) 2009-02-19
RS91404A (sr) 2007-02-05
KR20040103973A (ko) 2004-12-09
US20050159450A1 (en) 2005-07-21
MEP25608A (en) 2010-06-10
NO329065B1 (no) 2010-08-09
IL164400A0 (en) 2005-12-18
MXPA04010326A (es) 2005-07-05
HRP20040977A2 (en) 2004-12-31
HRP20040977B1 (hr) 2008-04-30
CA2481461C (en) 2010-01-12
JP2005527593A (ja) 2005-09-15
CY1108025T1 (el) 2013-09-04
UA78025C2 (en) 2007-02-15
FR2838739A1 (fr) 2003-10-24
DE60313602T2 (de) 2008-01-10
CA2481461A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
BRPI0415433A (pt) derivados de n-[fenil (alquilpiperidin-2-il)metil] benzamida, seu preparo e sua aplicação em terapêutica
WO2004013101A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
BRPI0415511A (pt) derivados de n-[fenil (pirrolidina-2-il) metil] benzamida e da n-[(azepan-2-il) fenilmetil] benzamida, preparação dos mesmos e aplicação dos mesmos em terapia
UY28149A1 (es) Compuestos quimicos
BR0207268A (pt) Quinazolinas como inibidores de mmp-13
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
EA200100486A1 (ru) Производные 2-уреидотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств
BR9806413A (pt) Composto e uso do mesmo
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
ECSP066667A (es) Derivados de ciclohexano espirociclicos
ATE357142T1 (de) 7-aminotriazolopyrimidine zur bekämpfung von schadpilzen
BR1100931A (pt) Compostos derivados de aril-heteroaril carbinóis, processos para a preparação dos compostos, composições farmacêuticas, e, uso dos compostos derivados de aril-heteroaril carbinóis
AR055878A1 (es) Derivados de ciclopropanocarboxamida
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
DE69815137D1 (de) Epoxybernsteinsäureamid-derivate
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
BR0308309A (pt) Derivados de isoxazolina amino substituìdo e seu uso como antidepressivos
EA200400666A2 (ru) Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
BR0314164A (pt) Derivados de aroil-piperidina
AR048112A1 (es) Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
BR0211179A (pt) Compostos, processo para preparar os mesmos, e, composição adequada e método para controlar fungos fitopatogênicos
UY26887A1 (es) Nuevas etanolaminas y etilendiaminas sustituídas con fenilo y fenilalquilo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.